Development of chronic hepatic porphyria (porphyria cutanea tarda) with inherited uroporphyrinogen decarboxylase deficiency under exposure to dioxin

• 1.1. Exposure to dioxin triggered a clinically manifest chronic hepatic porphyria (porphyria cutanea tarda) in two patients (brother and sister) with hereditary uroporphyrinogen decarboxylase deficiency.
• 2.2. The patients showed a decrease of erythrocyte uroporphyrinogen decarboxylase activity to ~ 50% of controls even in reinvestigations after three years, whereas clinical symptoms and porphyrinuria had improved considerably. Only a subclinical phase of chronic hepatic porphyria persisted. Subnormal uroporphyrinogen decarboxylase activity could be determined in altogether nine family members.
• 3.3. The remission of porphyria cutanea tarda into a subclinical phase occurred after chloroquine therapy. Subclinical phases of chronic hepatic porphyria (type A) in other family members remitted without special therapy.
• 4.4. Among the 60 persons dioxin-exposed by the Seveso accident, a secondary coproporphyrinuria was found in 22% of examined patients with transition to a subclinical chronic hepatic porphyria in 5 cases. The changes had subsided completely after one year. A persistence of the transition state in 3 cases is probably due to alcohol influence. None of these cases developed a porphyria cutanea tarda.
• 5.5. The investigations showed that a hereditary disposition is necessary for biochemical and clinical expression of chronic hepatic porphyria after a unique dioxin exposure. This is not given in the sporadic cases: after a unique dioxin exposure they indeed develop a symptomatic disturbance of porphyrin metabolism but not a clinically relevant chronic hepatic porphyria.
• 6.6. We conclude that a unique acute exposure to dioxin can trigger the chronic hepatic porphyria disease process in persons with an underlying genetic abnormality of uroporphyrinogen decarboxylase.

     

Monopyrroles in porphyria,psychosis and lead exposure

• 1.1. It has been shown that the monopyrrole other than porphobilinogen excreted in excess in acute porphyria is 3-ethyl-5-hydroxy-4,5-dimethyl-Δ³-pyrrolin-2-one (hydroxyhaemopyrrole lactam). A gas liquid chromatographic method has been developed for measurement of the concentrations of this compound. Hydroxyhaemopyrrole lactam was measured in the urine of patients with porphyria, psychiatric in-patients and subjects with industrial lead exposure. Concentrations were found to be raised in porphyria, but no correlation could be found between the concentrations of this compound and current clinical condition. In psychiatric patients, there was again significant elevation of hydroxyhaemopyrrole lactam, although no such rise could be found in lead workers. The studies in the lead workers and porphyria patients would suggest that there is an association between the concentrations of hydroxyhae-mopyrrole lactam in urine and porphobilinogen excretion.
• 2.2. The effects of the monopyrroles; hydroxyhaemopyrrole lactam; haemopyrrole; hydroxykryptopyr-role lactam; kryptopyrrole phyllopyrrole and ethyl-3-acetyl-2,4-dimethyl-pyrrole-5-carboxylate (EADC), have been examined on porphyrin metabolism in the rat. All significantly raised urinary porphyrin excretion and hepatic porphyrin concentrations. Hydroxyhaemopyrrole lactam caused an increase in the excretion of porphyrins associated with an increase in the activity of the rate-limiting enzyme of haem biosynthesis, δ-aminolaevulinic acid synthase. These results suggest some association between such pyrrole production and the biochemical changes found in acute porphyria.

     

Acute hepatic porphyria syndrome with porphobilinogen synthase defect

On the basis of metabolite and enzyme studies a new type of acute hepatic porphyria with porphobilinogen synthase defect and repeated intermittent acute manifestations, abdominal colics, tachycardia and hypertension, and a persistent neurological syndrome was found in two young male patients. The main characteristic features are the following:

• 1.1. High urinary δ-aminolevulinic acid excretion( ⪢ 1 mmol/24hr), slight increase of porphobilinogen (up to 25 μmol/24 hr) and high increase of porphyrins (up to 22 μmol/24 hr) with coproporphyrin dominance.
• 2.2. Normal fecal and liver porphyrins.
• 3.3. Slight increase of erythrocyte protoporphyrin.
• 4.4. Decrease of porphobilinogen synthase activity in erythrocytes in both cases below 1% of healthy and not lead-exposed persons; normal activities of uroporphyrinogen synthase and decarboxylase in erythrocytes.
• 5.5. Low-normal lead concentrations in blood and low-normal lead excretion in urine in both cases; normal lead content in bone.
• 6.6. Normal plasma and urinary amino acids.
• 7.7. Irrelevant hepatological (liver biopsy), general clinical chemical and hematological findings.
• 8.8. Diminished activity of porphobilinogen synthase in nearly all family members of both patients. From these investigations it can be concluded that there is no exogeneous, “toxic” cause of this porphyria. Porphobilinogen synthase in lead poisoning is not diminished to such an extent as demonstrated here; in contrast to lead intoxication, porphobilinogen synthase activity cannot be activated or reactivated by thiols. All clinical and pathobiochemical data point at a new enzymatic type of endogeneous acute hepatic porphyria with intermittent acute manifestations, clinically analogous to so-called acute intermittent porphyria. Porphyrin precursors and porphyrin excretion both reflects the enzymatic defect and the regulatory consequences starting with the induction of δ-aminolevulinic acid synthase.

     

Comparison of the porphyrin patterns in patients with porphyria cutanea tarda in Czechoslovakia and Denmark

• 1.1. The incidence of porphyria cutanea tarda (PCT) has increased considerably in Denmark during the last decade (Table 1) but is much higher in Czechoslovakia than in Denmark.
• 2.2. We therefore made a detailed study of the urinary porphyrin excretion pattern in 10 cases of PCT from Copenhagen and 10 from Prague.
• 3.3. The results are presented (Table 2). They show no simple pattern.
• 4.4. Comparison with the type subdivision of Doss et al. (Table 3) and the important findings of Piñol Aguade et al. show that such elaborate type division, involving considerable and time-consuming analytical work, belong to research and have limited value in clinical work.

     

CEP192 interacts physically and functionally with the K63-deubiquitinase CYLD to promote mitotic spindle assembly

CEP192 is a centrosome protein that plays a critical role in centrosome biogenesis and function in mammals, Drosophila and C. elegans.^1-6 Moreover, CEP192-depleted cells arrest in mitosis with disorganized microtubules, suggesting that CEP192’s function in spindle assembly goes beyond its role in centrosome activity and pointing to a potentially more direct role in the regulation of the mitotic microtubule landscape.⁷ To better understand CEP192 function in mitosis, we used mass spectrometry to identify CEP192-interacting proteins. We previously reported that CEP192 interacts with NEDD1, a protein that associates with the γ-tubulin ring complex (γ-TuRC) and regulates its phosphorylation status during mitosis.⁸ Additionally, within the array of proteins that interact with CEP192, we identified the microtubule binding K63-deubiquitinase CYLD. Further analyses show that co-depletion of CYLD alleviates the bipolar spindle assembly defects observed in CEP192-depleted cells. This functional relationship exposes an intriguing role for CYLD in spindle formation and raises the tantalizing possibility that CEP192 promotes robust mitotic spindle assembly by regulating K63-polyubiquitin-mediated signaling through CYLD.     

Establishing a network of specialist Porphyria centres - effects on diagnostic activities and services

Background

The porphyrias are a heterogeneous group of rare metabolic diseases. The full spectrum of porphyria diagnostics is usually performed by specialized porphyria laboratories or centres. The European Porphyria Initiative (EPI), a collaborative network of porphyria centres formed in 2001, evolved in 2007 into the European Porphyria Network (EPNET), where participating centres are required to adhere to agreed quality criteria. The aim of this study was to examine the state and distribution of porphyria diagnostic services in 2009 and to explore potential effects of increased international collaboration in the field of these rare diseases in the period 2006–2009.

Methods

Data on laboratory, diagnostic and clinical activities and services reported to EPI/EPNET in yearly activity reports during 2006 through 2009 were compared between reporting centres, and possible time trends explored.

Results

Thirty-five porphyria centres from 22 countries, five of which were non-European associate EPNET members, filed one or more activity reports to EPI/EPNET during the study period. Large variations between centres were observed in the analytical repertoire offered, numbers of analyses performed and type and number of staff engaged. The proportion of centres fulfilling the minimum criteria set by EPNET to be classified as a specialist porphyria centre increased from 80% to 94% during the study period.

Conclusions

Porphyria services are unevenly distributed, and some areas are probably still lacking in specialized porphyria services altogether. However, improvements in the quality of diagnostic services provided by porphyria centres participating in EPI/EPNET were observed during 2006 through 2009.

     

Assessing Susceptibility to Age-related Macular Degeneration with Proteomic and Genomic Biomarkers

Age-related macular degeneration (AMD) is a progressive disease and major cause of severe visual loss. Toward the discovery of tools for early identification of AMD susceptibility, we evaluated the combined predictive capability of proteomic and genomic AMD biomarkers. We quantified plasma carboxyethylpyrrole (CEP) oxidative protein modifications and CEP autoantibodies by ELISA in 916 AMD and 488 control donors. CEP adducts are uniquely generated from oxidation of docosahexaenoate-containing lipids that are abundant in the retina. Mean CEP adduct and autoantibody levels were found to be elevated in AMD plasma by ∼60 and ∼30%, respectively. The odds ratio for both CEP markers elevated was 3-fold greater or more in AMD than in control patients. Genotyping was performed for AMD risk polymorphisms associated with age-related maculopathy susceptibility 2 (ARMS2), high temperature requirement factor A1 (HTRA1), complement factor H, and complement C3, and the risk of AMD was predicted based on genotype alone or in combination with the CEP markers. The AMD risk predicted for those exhibiting elevated CEP markers and risk genotypes was 2–3-fold greater than the risk based on genotype alone. AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers. The results compellingly demonstrate higher mean CEP marker levels in AMD plasma over a broad age range. Receiver operating characteristic curves suggest that CEP markers alone can discriminate between AMD and control plasma donors with ∼76% accuracy and in combination with genomic markers provide up to ∼80% discrimination accuracy. Plasma CEP marker levels were altered slightly by several demographic and health factors that warrant further study. We conclude that CEP plasma biomarkers, particularly in combination with genomic markers, offer a potential early warning system for assessing susceptibility to this blinding, multifactorial disease.Age-related macular degeneration (AMD)¹ is the most common cause of legal blindness in the elderly in developed countries (1). It is a complex, progressive disease involving multiple genetic and environmental factors that can result in severe visual loss. Early risk factors include the macular deposition of debris (drusen) on Bruch membrane, the extracellular matrix separating the choriocapillaris from the retinal pigment epithelium (RPE). Later stages of “dry” AMD involve the degeneration of photoreceptor and RPE cells resulting in geographic atrophy. In “wet” AMD, abnormal blood vessels grow from the choriocapillaris through Bruch membrane (choroidal neovascularization (CNV)). CNV occurs in 10–15% of AMD cases yet accounts for over 80% of debilitating visual loss in AMD. Anti-vascular endothelial growth factor treatments can effectively inhibit the progression of CNV (1), and antioxidant vitamins and zinc can slow dry AMD progression for select individuals (2). However, there are no universally effective therapies for the prevention of dry AMD or the progression from dry to wet AMD nor are there therapies to repair retinal damage in advanced AMD. The prevalence of advanced AMD in the United States is projected to increase by 50% to ∼3 million by the year 2020 largely because of the rapidly growing elderly population (3). Accordingly early identification of AMD susceptibility and implementation of preventive measures are important therapeutic strategies (1).The molecular mechanisms causing AMD remain unknown, although inflammatory processes have been implicated by the identification of AMD susceptibility genes encoding complement factors (4–10) and the presence of complement proteins in drusen (11–13). Oxidative stress has long been associated with AMD pathology as shown by the finding that smoking significantly increases the risk of AMD (14) and that antioxidant vitamins can selectively slow AMD progression (2). A direct molecular link between oxidative damage and AMD was established by the finding that carboxyethylpyrrole (CEP), an oxidative protein modification generated from docosahexaenoate (DHA)-containing phospholipids, was elevated in Bruch membrane and drusen from AMD patients (11). Subsequently CEP adducts as well as CEP autoantibodies were found to be elevated in plasma from AMD donors (15), and CEP adducts were found to stimulate neovascularization in vivo, suggesting a role in the induction of CNV (16). From such observations, oxidative protein modifications were hypothesized to serve as catalysts of AMD pathology (11, 15, 17). In support of this hypothesis, mice immunized with CEP-adducted mouse albumin develop a dry AMD-like phenotype that includes sub-RPE deposits resembling drusen and RPE lesions mimicking geographic atrophy (18).Although identified AMD susceptibility genes account for over half of AMD cases (19), many individuals carrying AMD risk genotypes may never develop the disease. Likewise only a fraction of those diagnosed with early AMD progress to advanced stage disease with severe visual loss (2). Toward the discovery of better methods to predict susceptibility to advanced AMD, we quantified CEP adducts and autoantibodies in over 1400 plasma donors and also genotyped many of these donors for AMD risk polymorphisms in complement factor H (CFH) (4–7), complement C3 (9, 10), age-related maculopathy susceptibility 2 (ARMS2; also known as LOC387715) (19–22), and high temperature requirement factor A1 (HTRA1) (23, 24). The results demonstrate that combined CEP proteomic and genomic biomarker measurements are more effective in assessing AMD risk than either method alone.     

DISCO is key to successful centriole maturation

Centriole maturation is essential for ciliogenesis, but which proteins and how they regulate ciliary assembly is unclear. In this issue, Kumar et al. (2021. J. Cell Biol. https://doi.org/10.1083/jcb.202011133) shed light on this process by identifying a ciliopathy complex at the distal mother centriole that restrains centriole length and supports the formation of distal appendages.

The primary cilium plays a crucial role in embryonic development by allowing the integration of a variety of inputs, including chemical and mechanical signals. Primary cilia are found on most cell types; thereby, mutations in genes encoding cilia components may perturb many cellular functions, including airway mucus clearance, mechanosensation, and cell signaling, which are central regulators of organ function and homeostasis. Numerous mutations leading to ciliary dysfunction have been identified in recent years and thus linked to human cilia-related diseases, called ciliopathies (1, 2). Some of these mutations affect components of the centrioles, which are cytoplasmic cylindrical structures composed by triplets of microtubules arranged in a ninefold symmetry.Cilia originate from centrioles and are anchored to the cell surface. In most mammalian cells, centrioles are present within the centrosome, the main organizing center of microtubules. During G1 phase, cells have one centrosome containing two centrioles of different ages. The older mother centriole is distinguished from the younger daughter centriole by the presence of two sets of appendages organized around its circumference. The centrosome duplicates in S phase and, as a result, a new centriole is formed orthogonally to each parent centriole. The new centrioles subsequently elongate during S and G2 phases, and each daughter cell inherits a parent and a newly formed centriole after mitosis. During this transition, new centrioles become daughter centrioles, and the daughter centriole from the previous cycle acquires appendages to mature into a mother centriole. Distal appendages (DAs) are essential for anchoring the mother centriole to the plasma membrane and for the formation of a cilium (2). The formation of a mature centriole competent for ciliogenesis is therefore a complex process taking place over three successive cell cycles.Different molecular factors required for the progressive maturation of centrioles and the assembly of DAs have been identified in the past, and perturbation of their function has been linked to ciliopathies (2, 3). However, the precise mechanism by which DAs are assembled onto centrioles remains elusive. In this issue, Kumar et al. focused their attention on CEP90, a poorly characterized protein whose mutations have been implicated in several ciliopathies (4). CEP90 is a component of centriolar satellites, which are proteinaceous granules located at the periphery of the centrosome (5, 6). Using a combination of expansion microscopy and structured illumination super-resolution microscopy techniques, the authors found that CEP90 also localized to centrioles, where it formed a discontinuous ring with a ninefold symmetry. CEP90 localized near a well-characterized DA component, CEP164, which was consistent with CEP90 being present at the base of these appendages. Then, they searched for CEP90 interactors. For that, the researchers first had to circumvent the shortcoming of discriminating between interactions that may take place at the centrosome from those occurring within centriolar satellites. To get around this, Kumar et al. used a cell line in which satellite assembly is inhibited. Among the candidates they found interacting with CEP90 at the centrosome were OFD1 and Moonraker (MNR), which are two proteins previously associated with multiple ciliopathies. OFD1 is a centriole component required to restrict centriole elongation and assemble DAs (7). MNR, also called OFIP or KIAA073, is a satellite component necessary for cilia formation (8). Making again use of super-resolution microscopy, the authors showed that all three proteins colocalized at the centriole distal end, with the MNR protein being the closest to the centriole wall, so they named this newly identified complex after DISCO (distal centriole complex).Next, Kumar et al. elegantly demonstrated that, as previously shown for OFD1 (7), inactivating either CEP90 or MNR led to the absence of cilia in cells. In mice, deficiency of any of these proteins resulted in Hedgehog signaling inhibition and early arrest of embryonic development. As reported for OFD1-deficient cells, loss of MNR in human cells resulted in overly long centrioles. However, centriole length was normal in CEP90-deficient cells, suggesting partially distinct functions between members of the DISCO complex. The authors noted that ciliogenesis was blocked at an early stage in CEP90^−/− and MNR^−/− cells and, given that DAs are essential for centriole anchoring and ciliogenesis, they decided to examine DA organization in these cells (4). Indeed, they found that DA components, such as CEP83, were not recruited during centriole maturation in MNR^−/− or CEP90^−/− cells, and DAs were not detected by electron microscopy. These findings pointed out that CEP90 and MNR, like OFD1, were required for the assembly of DAs.Since CEP90 is required for satellite accumulation around the centrosome, and satellites are, in turn, essential for ciliogenesis (6), one possible explanation to their results is that CEP90 might affect DA assembly indirectly via its role in satellite localization. To answer this question, the authors again used cells lacking centriolar satellites. CEP90 was correctly localized at centriole distal ends in these cells, and DAs were formed, supporting a direct requirement for the centriolar pool of CEP90 in DA assembly. Putting all their data together, Kumar et al. proposed the following model: First, MNR is recruited to elongating centrioles, which, in turn, triggers the recruitment of OFD1 to arrest elongation at the end of the first cell cycle. MNR and OFD1 then recruit CEP90, which initiates the recruitment of DA components, including CEP83, at the end of the following cell cycle (Fig. 1). Thus, the DISCO complex allows for coupling the arrest of centriole elongation to centriole maturation across successive cell cycles.Open in a separate windowFigure 1.The DISCO complex restrains centriole elongation and initiates DA assembly. (1) The DISCO complex member MNR is recruited first at the distal end of assembling centrioles. MNR then recruits other members of the complex, including OFD1, which inhibits centriole elongation at the end of the first cell cycle, i.e., when newly formed centrioles become daughter centrioles (DCs). Other members of the complex include CEP90 and possibly also FOPNL. (2) At the end of the following cell cycle, as the daughter centriole matures into a mother centriole (MC), CEP90 initiates the recruitment of CEP83, the most upstream component in DA assembly. A previously identified interaction between OFD1 and another DA component, CEP89, might also contribute to DA organization (10). Proteins are drawn in contact with each other when an interaction or hierarchical recruitment was described (3, 4, 8, 11).Besides OFD1 and MNR proteins, Kumar et al. also identified a protein called FGFR1OP N-Terminal Like (FOPNL or FOR20) as a potential CEP90 interactor (4). Interestingly, this interaction was confirmed in a recent study describing that a complex containing CEP90, OFD1, and FOPNL localizes at the distal end of Paramecium centrioles and is necessary for the recruitment of DA components and centriole docking in Paramecium and human cells (9). FOPNL was previously found in complex with MNR and OFD1 and shown to facilitate their interaction (8). Together, these data suggest that the DISCO complex could also include FOPNL. The functional similarities of some of the components of the DISCO complex between Paramecium and humans strongly suggest that the role of DISCO in centriole maturation and ciliogenesis is broadly conserved across species.Previous studies in different organisms have underpinned the relevance of ciliopathy-associated proteins to ensure normal organism development and tissue function (1, 2). Overall, the findings by Kumar et al. highlight the critical role of a ciliopathy-associated protein complex at distal centrioles in building distal appendages, thus supporting centriole maturation and ciliogenesis in rodents and human cells (4).     

Reverse-phase purification and silica gel thin-layer chromatography of porphyrin carboxylic acids

Thin-layer chromatography on silica gel 60 plates in the solvent N,N-dimethylformamide/methanol/ethylene glycol/glacial acetic acid/1-chlorobutane/chloroform (4/35/6/0.4/18/20 by volume) separates porphyrin carboxylic acids by the number of free carboxyl groups. Coproporphyrins I and III and isocoproporphyrin are separated in 30 min, other porphyrins in 15 min. The N,N-dimethylformamide and acetic acid in the solvent strongly increase porphyrin fluorescence on the plates. Fading and diffusion of the fluorescent patterns is prevented by storage of the plates in the cold and dark without oxygen and with desiccant. In a preliminary step, porphyrins are purified in high yields, concentrated, and deacidified rapidly (2 min) by reversephase chromatography on cartridges containing a C₁₈ spacer or on Amberlite XAD-2 columns. The methods are applied to urines of porphyria patients and for following porphyrin ester hydrolysis.     

Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs

Ebola virus (EBOV) protein VP35 is a double-stranded RNA (dsRNA) binding inhibitor of host interferon (IFN)-α/β responses that also functions as a viral polymerase cofactor. Recent structural studies identified key features, including a central basic patch, required for VP35 dsRNA binding activity. To address the functional significance of these VP35 structural features for EBOV replication and pathogenesis, two point mutations, K319A/R322A, that abrogate VP35 dsRNA binding activity and severely impair its suppression of IFN-α/β production were identified. Solution nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography reveal minimal structural perturbations in the K319A/R322A VP35 double mutant and suggest that loss of basic charge leads to altered function. Recombinant EBOVs encoding the mutant VP35 exhibit, relative to wild-type VP35 viruses, minimal growth attenuation in IFN-defective Vero cells but severe impairment in IFN-competent cells. In guinea pigs, the VP35 mutant virus revealed a complete loss of virulence. Strikingly, the VP35 mutant virus effectively immunized animals against subsequent wild-type EBOV challenge. These in vivo studies, using recombinant EBOV viruses, combined with the accompanying biochemical and structural analyses directly correlate VP35 dsRNA binding and IFN inhibition functions with viral pathogenesis. Moreover, these studies provide a framework for the development of antivirals targeting this critical EBOV virulence factor.Ebola viruses (EBOVs) are zoonotic, enveloped negative-strand RNA viruses belonging to the family Filoviridae which cause lethal viral hemorrhagic fever in humans and nonhuman primates (47). Currently, information regarding EBOV-encoded virulence determinants remains limited. This, coupled with our lack of understanding of biochemical and structural properties of virulence factors, limits efforts to develop novel prophylactic or therapeutic approaches toward these infections.It has been proposed that EBOV-encoded mechanisms to counter innate immune responses, particularly interferon (IFN) responses, are critical to EBOV pathogenesis (7). However, a role for viral immune evasion functions in the pathogenesis of lethal EBOV infection has yet to be demonstrated. Of the eight major EBOV gene products, two viral proteins have been demonstrated to counter host IFN responses. The VP35 protein is a viral polymerase cofactor and structural protein that also inhibits IFN-α/β production by preventing the activation of interferon regulatory factor (IRF)-3 and -7 (3, 4, 8, 24, 27, 34, 41). VP35 also inhibits the activation of PKR, an IFN-induced, double-stranded RNA (dsRNA)-activated kinase with antiviral activity, and inhibits RNA silencing (17, 20, 48). The VP24 protein is a minor structural protein implicated in virus assembly and regulation of viral RNA synthesis, and changes in VP24 coding sequences are also associated with adaptation of EBOVs to mice and guinea pigs (2, 13, 14, 27, 32, 37, 50, 52). Further, VP24 inhibits cellular responses to both IFN-α/β and IFN-γ by preventing the nuclear accumulation of tyrosine-phosphorylated STAT1 (44, 45). The functions of VP35 and VP24 proteins are manifested in EBOV-infected cells by the absence of IRF-3 activation, impaired production of IFN-α/β, and severely reduced expression of IFN-induced genes, even after treatment of infected cells with IFN-α (3, 19, 21, 22, 24, 25, 28).Previous studies proposed that VP35 basic residues 305, 309, and 312 are required for VP35 dsRNA binding activity (26). VP35 residues K309 and R312 were subsequently identified as critical for binding to dsRNA, and mutation of these residues impaired VP35 suppression of IFN-α/β production (8). In vivo, an EBOV engineered to carry a VP35 R312A point mutation exhibited reduced replication in mice (23). However, because the parental recombinant EBOV into which the mutation was built did not cause disease in these animals, the impact of the mutation on viral pathogenesis could not be fully evaluated. Further, the lack of available structural and biochemical data to explain how the R312A mutation affects VP35 function limited avenues for the therapeutic targeting of critical VP35 functions. Recent structural analyses of the VP35 carboxy-terminal interferon inhibitory domain (IID) suggested that additional residues from the central basic patch may contribute to VP35 dsRNA binding activity and IFN-antagonist function (30). However, a direct correlation between dsRNA and IFN inhibitory functions of VP35 with viral pathogenesis is currently lacking.In order to further define the molecular basis for VP35 dsRNA binding and IFN-antagonist function and to define the contribution of these functions to EBOV pathogenesis, an integrated molecular, structural, and virological approach was taken. The data presented below identify two VP35 carboxy-terminal basic amino acids, K319 and R322, as required for its dsRNA binding and IFN-antagonist functions. Interestingly, these residues are outside the region originally identified as being important for dsRNA binding and IFN inhibition (26). However, they lie within the central basic patch identified by prior structural studies (26, 30). Introduction of these mutations (VP35 with these mutations is designated KRA) into recombinant EBOV renders this otherwise fully lethal virus avirulent in guinea pigs. KRA-infected animals also develop EBOV-specific antibodies and become fully resistant to subsequent challenge with wild-type (WT) virus. Our data further reveal that the KRA EBOV is immunogenic and likely replicates to low levels early after infection in vivo. However, the mutant virus is subsequently cleared by host immune responses. These data demonstrate that the VP35 central basic patch is important not only for IFN-antagonist function but also for EBOV immune evasion and pathogenesis in vivo. High-resolution structural analysis, coupled with our in vitro and in vivo analyses of the recombinant Ebola viruses, provides the molecular basis for loss of function by the VP35 mutant and highlights the therapeutic potential of targeting the central basic patch with small-molecule inhibitors and for future vaccine development efforts.     

High yield expression in a recombinant <Emphasis Type="Italic">E. coli</Emphasis> of a codon optimized chicken anemia virus capsid protein VP1 useful for vaccine development

Background

Chicken anemia virus (CAV), the causative agent chicken anemia, is the only member of the genus Gyrovirus of the Circoviridae family. CAV is an immune suppressive virus and causes anemia, lymph organ atrophy and immunodeficiency. The production and biochemical characterization of VP1 protein and its use in a subunit vaccine or as part of a diagnostic kit would be useful to CAV infection prevention.

Results

Significantly increased expression of the recombinant full-length VP1 capsid protein from chicken anemia virus was demonstrated using an E. coli expression system. The VP1 gene was cloned into various different expression vectors and then these were expressed in a number of different E. coli strains. The expression of CAV VP1 in E. coli was significantly increased when VP1 was fused with GST protein rather than a His-tag. By optimizing the various rare amino acid codons within the N-terminus of the VP1 protein, the expression level of the VP1 protein in E. coli BL21(DE3)-pLysS was further increased significantly. The highest protein expression level obtained was 17.5 g/L per liter of bacterial culture after induction with 0.1 mM IPTG for 2 h. After purification by GST affinity chromatography, the purified full-length VP1 protein produced in this way was demonstrated to have good antigenicity and was able to be recognized by CAV-positive chicken serum in an ELISA assay.

Conclusions

Purified recombinant VP1 protein with the gene's codons optimized in the N-terminal region has potential as chimeric protein that, when expressed in E. coli, may be useful in the future for the development of subunit vaccines and diagnostic tests.

     

Effect of Mutations in VP5* Hydrophobic Loops on Rotavirus Cell Entry

Experiments in cell-free systems have demonstrated that the VP5* cleavage fragment of the rotavirus spike protein, VP4, undergoes a foldback rearrangement that translocates three clustered hydrophobic loops from one end of the molecule to the other. This conformational change resembles the foldback rearrangements of enveloped virus fusion proteins. By recoating rotavirus subviral particles with recombinant VP4 and VP7, we tested the effects on cell entry of substituting hydrophilic for hydrophobic residues in the clustered VP5* loops. Several of these mutations decreased the infectivity of recoated particles without preventing either recoating or folding back. In particular, the V391D mutant had a diminished capacity to interact with liposomes when triggered to fold back by serial protease digestion in solution, and particles recoated with this mutant VP4 were 10,000-fold less infectious than particles recoated with wild-type VP4. Particles with V391D mutant VP4 attached normally to cells and internalized efficiently, but they failed in the permeabilization step that allows coentry of the toxin α-sarcin. These findings indicate that the hydrophobicity of the VP5* apex is required for membrane disruption during rotavirus cell entry.Cell entry by nonenveloped viruses requires disruption or perforation of a membrane and translocation of a modified virion or an infectious genome into the cytosol (30). A variety of mechanisms have evolved to carry out these steps. Viruses with double-stranded RNA (dsRNA) genomes, such as rotaviruses and orthoreoviruses, deliver an inner capsid particle to the cytosol of the target cell. The rotavirus inner capsid particle, known as a “double-layered particle” (DLP) because of its two-shell structure (Fig. ​(Fig.1),1), contains the 11 viral genome segments and the enzymes required for RNA synthesis and capping (13). The DLP remains intact throughout the infection, and new plus-sense RNA strands are made, capped, and extruded from the particle (17, 23). The outer layer of the virion (“triple-layered particle” [TLP]) contains two protein species, VP4 and VP7, which provide the molecular apparatus for cell attachment and membrane penetration.Open in a separate windowFIG. 1.Structures and model for conformational rearrangements of VP4. (Top center) Surface rendering from electron cryomicroscopy of a three-dimensional reconstruction of the rotavirus particle. A trypsin-cleaved VP4 spike (red) is boxed. The cutaway shows the multiple layers of the TLP. The VP7 layer is in yellow. The layers of the DLP are in green (VP6) and blue (VP2). (Top right) The VP4 primary structure indicating the boundaries of proteolytic products. (Bottom) Model for VP4 conformational rearrangements accompanying membrane penetration. (Step 1) Trypsin-activated VP4, in a schematic representation of a spike in roughly the orientation of the boxed spike in the rendering of a virion. The VP4 trimer has a 3-fold-symmetric “foot” but an asymmetrically organized projection. The ribbon diagram shows a dimeric form of the VP5 β-barrel domain (or antigen domain), which fits the dimer-clustered “body” of the projection, and the inset shows details of the three conserved hydrophobic loops that cap the β-barrel domain of VP5*. The hydrophobic residues mutated in this study are labeled. (Step 2) Dissociation of VP8* exposes the hydrophobic loops (shown as purple ovals) of VP5*. VP5* extends and engages a target membrane with the hydrophobic loops, probably from all three subunits. (Step 3) VP5* folds back to a stable trimeric structure, represented by the VP5CT crystal structure. This foldback is proposed to drive membrane penetration.VP4 makes up the “spikes,” which are evident on mature rotavirus particles only after tryptic cleavage of VP4 into fragments VP8* and VP5* (Fig. ​(Fig.1).1). This cleavage activates virions for efficient infectivity (12). Prior to cleavage, the outer parts of VP4 are probably flexibly linked to the “foot” (10), which is clamped by VP7 onto the underlying DLP. Each spike contains three copies of VP4. The virion-distal part of the spike appears to be dimer clustered and displaced from the local axis; electron cryomicroscopy has shown the foot to be a 3-fold-symmetric trimer (18). This unusual mismatch of symmetries suggests that the spike structure may be metastable and that a suitable trigger may induce it to rearrange further.Structural analyses of various VP4 domains, of VP7, and of DLPs and TLPs (2, 6, 10, 11, 18, 31, 33), together with biochemical studies of VP7, VP4, and VP4 fragments (8, 9, 28, 29, 32), suggest the model illustrated in Fig. ​Fig.1.1. Trypsin-cleaved VP4 forms the spike, in which the “body” regions of two of the three VP5* fragments cluster together; the two associated VP8* fragments cover the hydrophobic tips of these clustered VP5* β-barrel domains (designated in previous papers “antigen domains” [VP5Ag]). All three subunits contribute to the C-terminal foot. VP7, a calcium-stabilized trimer, locks the VP4 foot in place. Dissociation of VP7 (“uncoating”), induced by a lowered calcium concentration, allows VP5* to rearrange further into a symmetrical trimer, with the VP5* antigen domains rotated by roughly 180°, so that their hydrophobic tips point toward the foot. This step probably requires loss of VP8* and formation of a transient extended intermediate.The properties of recombinant VP4 in solution correlate with the steps of the model described above. Full-length recombinant VP4 is predominantly monomeric in solution (8). Successive cleavages with chymotrypsin and trypsin produce “VP5CT,” a fragment that coincides with VP5* at its N terminus but has lost residues corresponding roughly to the foot at its C terminus (Fig. ​(Fig.1)1) (8). It is an SDS-resistant trimer that remains associated unless it is heated to 95°C in SDS-PAGE sample buffer (8, 32). Authentic VP5* released from uncoated virions also forms an SDS-resistant trimer (32).Studies of the properties of VP4 fragments, prepared by proteolysis of monomeric VP4 or by release from virions, provide evidence for a transient, extended intermediate of VP5* (Fig. ​(Fig.1)1) and for its interaction with synthetic membranes (29). Digestion of recombinant VP4 with chymotrypsin and trypsin in the presence of liposomes leads to membrane association of the resulting VP5CT, but preformed VP5CT does not associate with liposomes added after cleavage and trimerization are complete. Authentic VP5* has similar properties: if released from virions (by chelating Ca²⁺) in the presence of liposomes, it associates with them, but it does not do so if the liposomes are added after uncoating. In both cases, the lipid bilayer appears to have captured a transient intermediate in the rearrangement to the folded back, trimeric species revealed by the VP5CT crystal structure.Three loops (designated BC, DE, and FG) form the hydrophobic patch that caps one end of the VP5* β-barrel domain (Fig. ​(Fig.1)1) (10, 31). The position of this patch makes it a likely candidate to mediate the membrane interactions described above; indeed, the FG loop amino acid sequence resembles that of an alphavirus fusion loop, suggesting that it could insert directly into a lipid bilayer. We report here experiments that test whether the hydrophobicity of the VP5* loops is important for rotavirus infectivity and for membrane association of the trimeric VP5* intermediate. Because sequential addition of recombinant VP4 and VP7 to rotavirus DLPs yields recoated particles (RPs) that are fully infectious after trypsin priming (28), we can incorporate VP4 with mutated hydrophobic residues to examine the progress of such particles along the cell entry pathway. We show that a modification in a VP4 hydrophobic loop reduces infectivity by blocking a membrane permeabilization step that follows cell attachment and endocytic internalization. The results support the proposal that these loops couple a conformational change in VP5* to disruption or perforation of an endosomal membrane.     

Virion Incorporation of the Herpes Simplex Virus Type 1 Tegument Protein VP22 Occurs via Glycoprotein E-Specific Recruitment to the Late Secretory Pathway

The mechanism by which herpesviruses acquire their tegument is not yet clear. One model is that outer tegument proteins are recruited by the cytoplasmic tails of viral glycoproteins. In the case of herpes simplex virus tegument protein VP22, interactions with the glycoproteins gE and gD have been shown. We have previously shown that the C-terminal half of VP22 contains the necessary signal for assembly into the virus. Here, we show that during infection VP22 interacts with gE and gM, as well as its tegument partner VP16. However, by using a range of techniques we were unable to demonstrate VP22 binding to gD. By using pulldown assays, we show that while the cytoplasmic tails of both gE and gM interact with VP22, only gE interacts efficiently with the C-terminal packaging domain of VP22. Furthermore, gE but not gM can recruit VP22 to the Golgi/trans-Golgi network region of the cell in the absence of other virus proteins. To examine the role of the gE-VP22 interaction in infection, we constructed a recombinant virus expressing a mutant VP22 protein with a 14-residue deletion that is unable to bind gE (ΔgEbind). Coimmunoprecipitation assays confirmed that this variant of VP22 was unable to complex with gE. Moreover, VP22 was no longer recruited to its characteristic cytoplasmic trafficking complexes but exhibited a diffuse localization. Importantly, packaging of this variant into virions was abrogated. The mutant virus exhibited poor growth in epithelial cells, similar to the defect we have observed for a VP22 knockout virus. These results suggest that deletion of just 14 residues from the VP22 protein is sufficient to inhibit binding to gE and hence recruitment to the viral envelope and assembly into the virus, resulting in a growth phenotype equivalent to that produced by deleting the entire reading frame.The herpesvirus tegument is the virion compartment located between the DNA-containing capsid and the virus envelope (6). Although it is well defined that the viral capsid assembles in the nucleus (37, 38) and the viral envelope is acquired from cellular membranes (3, 24), the mechanism of tegument protein acquisition is still to be established. At least 20 virus-encoded components are recruited into the herpes simplex virus type 1 (HSV-1) tegument (32), and there is increasing evidence to suggest that subsets of these proteins may be added as assembly progresses along the maturation pathway (28). To ensure efficient incorporation, it is likely that individual tegument proteins are specifically targeted to their cellular site of recruitment. Such targeting could involve interaction with a viral partner, a cellular partner, or both. A clearer understanding of how individual tegument proteins are acquired by newly assembling virions will help to define the herpesvirus assembly pathway.A number of protein-protein interactions between individual tegument proteins (13, 40, 42), and between tegument proteins and glycoproteins (19, 20, 22, 32), have been described that may provide useful insight into the assembly process. In particular, the interaction of tegument proteins with the cytoplasmic tails of virus glycoproteins provides an attractive mechanism for the virion recruitment of at least the outer components of the tegument. In the case of VP22, the homologues from pseudorabies virus (PRV) and HSV-1 have been shown to interact with the cytoplasmic tail of gE (19, 20, 32). However, the role of this interaction in virus infection has not yet been clearly defined and the fact that additional glycoprotein interactions have been described, with gM in the case of PRV and gD in the case of HSV-1, may point to potential redundancy in the mechanism of VP22 packaging (4, 19, 20). In addition, we and others have previously shown that HSV-1 VP22 interacts directly with a second tegument protein, namely, VP16 (13, 33), an interaction that could provide an alternative route for VP22 to enter the virion. In a previous study, we concluded that the region of VP22 containing its VP16 interaction domain was required but not sufficient for optimal VP22 packaging into the assembling virion, with an additional C-terminal determinant also involved (23). We also demonstrated that the same region of VP22 that was required for virion packaging was essential to target the protein to its characteristic cytoplasmic trafficking complexes, suggesting that these specific sites may be the location in the cell for VP22 assembly into the virion (23). Since that study, O''Regan and coworkers have reported that the C-terminal half of HSV-1 VP22 also contains the binding site for gE (32), providing a possible candidate for an additional VP22 binding partner. Furthermore, as HSV-1 VP22 has been shown to bind to gD and PRV VP22 interacts with gM, it is possible that the C terminus of VP22 contains a gD and/or a gM binding site (4, 20).In the present study, we aimed to clarify the molecular mechanism by which VP22 is recruited into the virus particle. We show that HSV-1 VP22 binds efficiently to VP16, gE, and gM in the infected cell, but we cannot detect an interaction with gD. We show that the packaging domain of VP22 binds to the cytoplasmic tail of gE but not gM and that the same region of VP22 is recruited to the secretory pathway by gE in the absence of other virus proteins. Finally, we show that a mutant VP22 protein lacking a 14-residue peptide from its packaging domain is unable to interact with gE during infection, exhibits a different subcellular localization, and fails to assemble into the virus particle. This is the first characterization of a single protein-protein interaction essential for the packaging of an HSV-1 tegument protein.